Cedric Francois
Net Worth

Last updated:

What is Cedric Francois net worth?

The estimated net worth of Dr. Cedric Francois is at least $52,041,203 as of 1 Mar 2024. He owns shares worth $8,349,682 as insider, has earned $37,391,521 from insider trading and has received compensation worth at least $6,300,000 in Apellis Pharmaceuticals, Inc..

What is the salary of Cedric Francois?

Dr. Cedric Francois salary is $1,050,000 per year as Co-Founder, Pres, Chief Executive Officer & Director in Apellis Pharmaceuticals, Inc..

How old is Cedric Francois?

Dr. Cedric Francois is 53 years old, born in 1972.

What stocks does Cedric Francois currently own?

As insider, Dr. Cedric Francois owns shares in one company:

Company Title Shares Price per share Total value
Apellis Pharmaceuticals, Inc. (APLS) Co-Founder, Pres, Chief Executive Officer & Director 313,662 $26.62 $8,349,682

What does Apellis Pharmaceuticals, Inc. do?

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS logo
APLS
Apellis Pharmaceuticals, Inc.
$26.62

Cedric Francois insider trading

Apellis Pharmaceuticals, Inc.

Dr. Cedric Francois has made 38 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 300,000 units of APLS stock on 1 Sep 2023. As of 1 Mar 2024 he still owns at least 313,662 units of APLS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 200,000 $4.31 $862,000
Option
Common Stock 50,000 $3.76 $188,000
Sale
Common Stock 62,503 $64.26 $4,016,255
Option
Common Stock 200,000 $4.31 $862,000
Sale
Common Stock 413 $65.68 $27,126
Sale
Common Stock 116,512 $64.92 $7,563,493
Sale
Common Stock 28,868 $62.21 $1,795,965
Sale
Common Stock 41,704 $62.96 $2,625,809
Option
Stock Option (Right to Buy) 50,000 $3.76 $188,000
Sale
Common Stock 3,962 $67.77 $268,493
Sale
Common Stock 2,843 $64.14 $182,344
Sale
Common Stock 13,431 $65 $872,961
Sale
Common Stock 10,284 $42.44 $436,453
Option
Stock Option (Right to Buy) 300,000 $2.67 $801,000
Sale
Common Stock 139,716 $41.7 $5,826,576
Option
Common Stock 300,000 $2.67 $801,000
Option
Common Stock 20,000 $2.67 $53,400
Option
Stock Option (Right to Buy) 20,000 $2.67 $53,400
Sale
Common Stock 7,528 $87.02 $655,056
Option
Common Stock 30,000 $2.67 $80,100
Option
Stock Option (Right to Buy) 30,000 $2.67 $80,100
Sale
Common Stock 934 $83.17 $77,682
Sale
Common Stock 1,800 $83.85 $150,921
Sale
Common Stock 14,611 $85.01 $1,242,066
Sale
Common Stock 3,007 $85.9 $258,304
Sale
Common Stock 2,120 $87.67 $185,869
Option
Common Stock 20,000 $2.67 $53,400
Option
Stock Option (Right to Buy) 20,000 $2.67 $53,400
Option
Common Stock 30,000 $2.67 $80,100
Option
Stock Option (Right to Buy) 30,000 $2.67 $80,100
Sale
Common Stock 30,000 $82.02 $2,460,720
Option
Stock Option (Right to Buy) 7,221 $13.85 $100,011
Option
Stock Option (Right to Buy) 20,000 $2.67 $53,400
Option
Common Stock 20,000 $2.67 $53,400
Option
Common Stock 100,000 $3.76 $376,000
Option
Stock Option (Right to Buy) 100,000 $3.76 $376,000
Option
Common Stock 7,221 $13.85 $100,011
Option
Common Stock 30,000 $2.67 $80,100
Sale
Common Stock 30,000 $62.74 $1,882,320
Option
Stock Option (Right to Buy) 30,000 $2.67 $80,100
Option
Stock Option (Right to Buy) 100,000 $3.76 $376,000
Option
Common Stock 100,000 $3.76 $376,000
Option
Common Stock 15,000 $3.76 $56,400
Option
Stock Option (Right to Buy) 15,000 $3.76 $56,400
Option
Stock Option (Right to Buy) 6,688 $14.95 $99,986
Option
Stock Option (Right to Buy) 28,200 $2.67 $75,294
Option
Common Stock 28,200 $2.67 $75,294
Option
Common Stock 6,688 $14.95 $99,986
Sale
Common Stock 24,449 $52.07 $1,273,059
Sale
Common Stock 3,751 $51.97 $194,932
Option
Common Stock 14,410 $4.31 $62,107
Option
Stock Option (Right to Buy) 14,410 $4.31 $62,107
Option
Common Stock 71,777 $4.04 $289,620
Option
Stock Option (Right to Buy) 71,777 $4.04 $289,620
Sale
Common Stock 5,000 $52.16 $260,800
Option
Stock Option (Right to Buy) 40,000 $3.76 $150,400
Option
Common Stock 40,000 $3.76 $150,400
Sale
Common Stock 5,000 $39.38 $196,900
Sale
Common Stock 5,000 $34.46 $172,300
Sale
Common Stock 5,000 $30.96 $154,800
Sale
Common Stock 3,457 $30 $103,710
Sale
Common Stock 1,543 $30 $46,290
Sale
Common Stock 5,000 $32.12 $160,600
Sale
Common Stock 5,000 $30.21 $151,050
Sale
Common Stock 5,000 $29.92 $149,600
Sale
Common Stock 5,000 $29.77 $148,850
Option
Stock Option (Right to Buy) 30,637 $2.14 $65,563
Option
Common Stock 30,637 $2.14 $65,563
Sale
Common Stock 35,637 $21.86 $778,882
Option
Common Stock 30,637 $2.14 $65,563
Option
Stock Option (Right to Buy) 30,637 $2.14 $65,563
Option
Common Stock 30,637 $2.14 $65,563
Option
Stock Option (Right to Buy) 30,637 $2.14 $65,563
Sale
Common Stock 35,637 $21.4 $762,739
Option
Common Stock 30,637 $2.14 $65,563
Option
Stock Option (Right to Buy) 30,637 $2.14 $65,563
Option
Stock Option (Right to Buy) 30,637 $2.14 $65,563
Option
Common Stock 30,637 $2.14 $65,563
Option
Common Stock 30,638 $2.14 $65,565
Sale
Common Stock 35,638 $42.06 $1,498,899
Option
Stock Option (Right to Buy) 30,638 $2.14 $65,565
Sale
Common Stock 5,000 $27.95 $139,750
Sale
Common Stock 5,000 $27.28 $136,405
Sale
Common Stock 5,000 $26.1 $130,500
Sale
Common Stock 5,000 $26.86 $134,320
Option
Stock Option (Right to Buy) 37,505 $2.67 $100,138
Option
Common Stock 37,505 $2.67 $100,138
Option
Stock Option (Right to Buy) 10,000 $2.14 $21,400
Option
Common Stock 10,000 $2.14 $21,400
Sale
Common Stock 10,000 $26.87 $268,720
Option
Stock Option (Right to Buy) 275,000 $2.14 $588,500
Option
Common Stock 275,000 $2.14 $588,500

Apellis Pharmaceuticals key executives

Apellis Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: